Search

Displaying results 2701 - 2710 of 10000 in total
  1. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.

  2. Drug

    Tolevamer

    go.drugbank.com/drugs/DB01344
    Approved

    It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. … It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.

  4. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  5. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … -, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.

  6. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

    Categories: Vasodilators Used in Cardiac Diseases
  7. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings. … Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use.

  8. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

  9. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801] … prevention to become available in the U.S.

    Categories: Complex Mixtures
  10. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.